21 Sep 2026

CRC Research Update — September 21, 2026

Creator: The CRC Digest
Published: 2026-09-21T11:30:49Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

TRIAL DATA
PEGASUS Phase 2 Trial Tests ctDNA-Guided Adjuvant Therapy in Colon Cancer
A Phase 2 trial is evaluating whether circulating tumor DNA can guide adjuvant treatment decisions in colon cancer patients after surgery. (Oncodaily)
RESEARCH
Early-Onset CRC Shows Distinct Molecular Features, Gut Microbiome Implicated
A systematic review finds that most early-onset colorectal cancer cases occur without known genetic predispositions, and emerging evidence points to the gut microbiome as a potential contributor. (Oncology Therapy)
LIVING WITH CRC
Oxaliplatin-Induced Neuropathy Tracked in Survivors Up to 2 Years Post-Treatment
A prospective study of 106 stage II-III colon cancer patients treated with adjuvant CAPOX examined associations between oxaliplatin dosing and chemotherapy-induced peripheral neuropathy, with assessments continuing up to 24 months after treatment. (International Journal of Cancer)
SCREENING
Mobile Health Intervention Increases CRC Awareness in Young Black Men
A 14-day pilot mHealth intervention called PRISM showed preliminary evidence of increasing colorectal cancer knowledge among 20 Black men aged 18-25 in Virginia. (Ethnicity & Health)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

RESEARCH
Hereditary Syndromes Account for Only 20-25% of Early-Onset Cases
A comprehensive review reports that hereditary cancer syndromes account for 20-25% of early-onset colorectal cancer cases, with most occurring in the absence of known genetic predispositions. (Oncology Therapy)

Today's research spans biomarker-guided treatment strategies, long-term survivorship outcomes, and efforts to address disparities in screening and early detection.

Get CRC research intelligence delivered weekly, free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest